Cogentis is a pre-clinical, pre-money biotech working with the NIH and academia to cure Alzheimer’s Disease. We are developing an unprecedented patented therapy that overcomes previous obstacles to reverse the underlying disease process. Rather than inhibiting normal biology, our nontoxic approach restores normal function and has already been shown to reverse the disease in mouse models of Alzheimer’s. Promising data points to using a similar therapy to treat Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and other forms of dementia like frontotemporal dementia and progressive supranuclear palsy. We are raising an initial $3MM to propel us through the IND process with a goal to go to Phase I trials by 2023.